3-pyranone | 28743-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 3-pyranone
• 英文别名: dihydro-2H-pyran-3(4H)-one；dihydro-pyran-3-one；dihydropyran-3-one；2,4-Dihydropyran-3-one；4H-pyran-3-one
• CAS: 28743-04-6
• 化学式: C₅H₆O₂
• 分子量: 98.1014
• InChiKey: MALOBWMOORWUQW-UHFFFAOYSA-N

物化性质

• 保留指数：
  995.3

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-pyranone 生成 3,6-二氢-5-羟基-2H-吡喃-4-羧酸乙酯
  参考文献：
  名称：

  EP1348443

  摘要：

  公开号：

文献信息

• [EN] PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] COMPOSES DE PYRAZINE COMME INHIBITEURS DE PHOSPHODIESTERASE 10
  申请人：AMGEN INC

  公开号：WO2010057121A1

  公开（公告）日：2010-05-20

  Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• Compounds and their use as BACE Inhibitors
  申请人：Csjernyik Gabor

  公开号：US20120165347A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。
• NOVEL TRPA1 ANTAGONISTS
  申请人：Bilodeau Mark T.

  公开号：US20120196894A1

  公开（公告）日：2012-08-02

  The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function. The present invention further relates to methods and compositions that antagonize both a function of TRPA1 and a function of one or more additional TRP channels.

  本发明涉及调节至少一个TRP家族成员的组合物和方法。具体而言，本发明涉及新型TRPA1拮抗剂及其在治疗疼痛（如慢性炎症性和神经病性疼痛）中的应用。能够调节一个或多个TRPA1功能的化合物在许多方面都很有用，包括但不限于维持钙离子平衡；维持钠离子平衡；调节细胞内钙离子水平；调节膜极化（膜电位）；调节阳离子水平；和/或治疗或预防与钙离子平衡、钠离子平衡、钙或钠离子失调或膜极化/去极化（包括低和高兴奋性）有关的疾病、障碍或病况，和/或治疗或预防与TRPA1表达或功能调节或失调有关的疾病、障碍或病况。本发明还涉及同时拮抗TRPA1的一个功能和一个或多个额外TRP通道的功能的方法和组合物。
• TRPA1 antagonists
  申请人：Bilodeau Mark T.

  公开号：US08829196B2

  公开（公告）日：2014-09-09

  The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function. The present invention further relates to methods and compositions that antagonize both a function of TRPA1 and a function of one or more additional TRP channels.

  本发明涉及调节至少一种TRP家族成员的组合物和方法。具体地，本发明涉及新型TRPA1拮抗剂及其在治疗疼痛（如慢性炎症性和神经病性疼痛）方面的应用。能够调节一个或多个TRPA1功能的化合物在许多方面都有用，包括但不限于维持钙离子稳态；维持钠离子稳态；调节细胞内钙离子水平；调节膜极化（膜电位）；调节阳离子水平；和/或治疗或预防与钙离子稳态、钠离子稳态、钙离子或钠离子失稳、膜极化/去极化（包括低和高兴奋性）或调节或调节失调TRPA1表达或功能相关的疾病、疾病或病情。本发明还涉及拮抗TRPA1功能和一个或多个额外TRP通道功能的方法和组合物。
• Enantioselective Organocatalytic α-Fluorination of Cyclic Ketones
  作者：Piotr Kwiatkowski、Teresa D. Beeson、Jay C. Conrad、David W. C. MacMillan

  DOI：10.1021/ja111163u

  日期：2011.2.16

  The first highly enantioselective alpha-fluorination of ketones using organocatalysis has been accomplished. The long-standing problem of enantioselective ketone alpha-fluorination via enamine activation has been overcome via high-throughput evaluation of a new library of amine catalysts. The optimal system, a primary amine functionalized Cinchona alkaloid, allows the direct and asymmetric a-fluorination of a variety of carbo- and heterocyclic substrates. Furthermore, this protocol also provides diastereo-, regio-, and chemoselective catalyst control in fluorinations involving complex carbonyl systems.